Literature DB >> 3497269

Genetic and molecular genetic studies of murine and human lupus.

A D Steinberg, D M Klinman, D L Kastner, M F Seldin, W C Gause, C L Scribner, J L Britten, J N Siegel, J D Mountz.   

Abstract

Mice and humans with systemic lupus erythematosus (SLE) have been studied with regard to cellular, genetic and molecular genetic abnormalities. B cell hyperactivity and autoantibody production are the hallmarks of this illness. In humans with SLE, there is increased stem cell, B cell precursor and B cell proliferation. The same is true of NZB mice. In lpr/lpr and gld/gld mice, marked expansion of a subpopulation of T cells allows extrathymic terminal T cell maturation and secondary B cell hyperactivity. Androgens suppress these processes and polyclonal immune activators accelerate them. Three types of genes are identified: inducing genes, accelerating genes and background genes. These give rise to abnormal expression of various cellular oncogenes, T cell receptor genes and immunoglobulin genes. The data suggest that abnormal immune regulation plays a critical role in the development of SLE, with polyclonal B cell activation being common to both mice and humans with SLE. Different genetic and cellular abnormalities underlie the ultimate syndrome, the common denominator, generalized autoimmunity, that we call SLE.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497269

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  3 in total

1.  Effect of glucan on murine lupus evolution and on host resistance to Klebsiella pneumoniae.

Authors:  H A Harima; N F Mendes; E M Mamizuka; M Mariano
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

2.  Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice.

Authors:  W M Wu; J L Suen; B F Lin; B L Chiang
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

3.  Evidence for aberrant regulation of MAP kinase signal transduction pathway in peripheral blood mononuclear cells in patients with active celiac disease.

Authors:  E Broide; E Scapa; O Bloch; M Shapiro; N A Kimchi; G Ben-Yehudah; M J Rapoport
Journal:  Dig Dis Sci       Date:  2008-09-12       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.